top of page

Biopharma Daily Stock Updates - 01/07/21

Updated: Jan 13, 2021

$XBI $149.21 (+4.11%) 📈


$NVAX (+3.56%) - Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine


$SRPTA (+1.50%) - Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

$ALNY (+9.91%) - Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

$MRUS (-1.16%) - Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

$GLYC (+4.32%) - APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

$ALDX (+26.42%) - Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

$BTNX (+2.78%) - BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

$AQST (+3.25%) - Aquestive Therapeutics Provides Business Update

$DVAX (+6.52%) - Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

$KALA (+3.96%) - Kala Pharmaceuticals Announces Availability of EYSUVIS™ for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

$LOGC (+1.85%) - LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute

$PRAX (+4.62%) - Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs


$CERC (+2.11%) - Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants

$ARCT (+35.65%) - Wells Fargo Initiates Coverage On Arcturus Therapeutics with Overweight Rating

$AMRN (+9.69%) - Amarin Provides Preliminary 2020 Results and 2021 Outlook

$EIGR (-8.06%) - Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans

$RVNC (+8.79%) - Revance Provides Corporate Update and Anticipated Milestones for 2021

bottom of page